Adverse Effects and Comorbidities
  • Featured content
    In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
    Date Posted: 6/15/2015
  • Featured content
    In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
    Date Posted: 6/15/2015
  • Featured content
    Watch as HIV experts, Joseph J. Eron, Jr., MD; W. David Hardy, MD; and Paul E. Sax, MD, discuss their approach to selecting first-line antiretroviral therapy for HIV-infected patients.
  • Featured content
    How do the DHHS guidelines and recent switch studies affect our decision to change regimens in virologically suppressed patients?
    Date Posted: 5/27/2015
  • Featured content
    In this case-based example, I describe the available options for single-tablet ART regimens in a patient with CVD risk factors and renal disease, including how recent data influence the management strategy.
    Date Posted: 4/21/2015
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 651 Shown
  • HIV and Cardiovascular Disease: How Worried Should We Be?

    In this downloadable slideset, David A. Wohl, MD, reviews the association between HIV and cardiovascular disease, including potential contributing factors and best practices in prevention.
    Date Posted: 6/26/2015
  • ART Update 2015

    In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
    Date Posted: 6/15/2015
  • Video Module cme-icon ce-icon

    Integrating Recent Data When Selecting First-line Antiretroviral Therapy

    Watch as HIV experts, Joseph J. Eron, Jr., MD; W. David Hardy, MD; and Paul E. Sax, MD, discuss their approach to selecting first-line antiretroviral therapy for HIV-infected patients.
    Faculty: Joseph J. Eron, Jr. MD, W. David Hardy MD, Paul E. Sax MD
    Released: 6/10/2015
  • Integrating Recent Data When Selecting First-line Antiretroviral Therapy

    Use this downloadable slideset as a companion guide to the short video module in which HIV experts, Joseph J. Eron, Jr., MD; W. David Hardy, MD; and Paul E. Sax, MD, discuss their approach to selecting first-line antiretroviral therapy for HIV-infected patients.
    Date Posted: 6/10/2015
  • Strategic ART Switching: If It’s Not Broken, Should We Still Fix It?

    David A. Wohl MD - 5/27/2015 1 comment / Last Comment: 6/8/2015
    How do the DHHS guidelines and recent switch studies affect our decision to change regimens in virologically suppressed patients?
  • Analyzing NA-ACCORD: Should You Avoid Abacavir In Patients With Cardiovascular Risk?

    Josep M. Llibre MD - 5/15/2015 4 comments / Last Comment: 6/13/2015
    The recent NA-ACCORD data presented at CROI 2015 has reignited discussion on the potential association between abacavir exposure and MI. But there are several limitations of this analysis to consider before altering your practice.
  • Considerations on the Use of Fixed-Dosed Combination Therapy in a Patient With Multiple Comorbidities

    Eric S. Daar MD - 4/21/2015 2 comments / Last Comment: 6/13/2015
    In this case-based example, I describe the available options for single-tablet ART regimens in a patient with CVD risk factors and renal disease, including how recent data influence the management strategy.
  • Learning Module cme-icon

    Clinical Impact of Data From the 2015 Conference on Retroviruses and Opportunistic Infections

    Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; and Kathleen E. Squires, MD, guide participants through interpretation of key studies from this important annual conference and applying results to clinical practice.
    Faculty: Joseph J. Eron, Jr. MD, Joel E. Gallant MD, MPH, Kathleen E. Squires MD
    Released: 4/17/2015
  • How I Decided Whether to Stop a Potentially Inactive NRTI in a Patient Receiving a Suppressive Regimen

    Renslow Sherer MD - 4/17/2015 2 comments / Last Comment: 5/20/2015
    How does the risk of ongoing NRTI-related toxicity in a patient weigh up against the limited antiviral contribution to a suppressive regimen? The data that informed my decision.
  • HIV Seattle Update

    Expert faculty members Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; and Kathleen E. Squires, MD, outline key studies from this important annual conference.
    Date Posted: 3/12/2015
10 of 651 Shown
Show 10 More
Loading...